Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

Journal of Bone and Joint Surgery - Series B

Volumn 91, Issue 5, 2009, Pages 636-644

  Eriksson, B I ^a,b   Kakkar, A K ^a,c   Turpie, A G G ^a,d   Gent, M ^a,d   Bandel, T J ^a,e   Homering, M ^a,e   Misselwitz, F ^a,e   Lassen, M R ^a,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MCMASTER UNIVERSITY   (Canada)

^e BAYER PHARMA AG   (Germany)

^f Hoersholm Hospital   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; RIVAROXABAN; UNCLASSIFIED DRUG; XARELTO;

ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; HIP ARTHROPLASTY; HUMAN; INCIDENCE; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION; WOUND INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 65649094404     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.91B5.21691     Document Type: Article

References (26)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:381-453.
2. Bergqvist D. Long-term prophylaxis following orthopaedic surgery. Haemostasis 1993;23:27-31. (Pubitemid 23116271)
3. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:122-130 (Pubitemid 41289268)
4. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-764 (Pubitemid 47555066)
5. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-394
6. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87-97.
7. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521 (Pubitemid 41632877)
8. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775
9. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39
10. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786
11. No authors listed. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for good clinical practice. http://www.ich.org/LOB/media/MEDIA482.pdf (date last accsesed 6 April 2009).
12. No authors listed. World Medical Assocation Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/pdf/17c.pdf (date last accessed 6 April 2009).
13. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-144
14. No authors listed. Medical Dictionary for Regulatory Activities. http://www.meddramsso.com/MSSOWeb/index.htm (date last accessed 6 April 2009).
15. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg [Br] 2007;89-B:799-807.
16. Cook TM, Mihai R, Wildsmith JA. A national census of central neuraxial block in the UK: results of the snapshot phase of the Third National Audit Project of the Royal College of Anaesthetists. Anaesthesia 2008;63:143-146
17. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 2007;62:1154-1160 (Pubitemid 47556416)
18. Xarelto® Summary of Product Characteristics. http://www.xarelto com/html/ downlads/Xarelto-Summary-of-Product-Characteristics-30Sept2008.pdf (date last accessed 31 March 2009).
19. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006;102:1884-1898 (Pubitemid 43799873)
20. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003;1:1906-1913
21. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840
22. Perzborn E, Harwardt M. Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost 2007;5 (Suppl 2):Abstract.
23. Perzborn E, Tinel H. FEIBA reverses the effects of a high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 2008;36(Suppl 1):A40.
24. Tinel H, Huetter J, Perzborn E. Recombinant factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban: a novel, oral factor Xa inhibitor in rats. J Thromb Haemost 2007;5 (Suppl 2):Abstract.
25. Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-673
26. Negrini C, Diamantopoulos A, Forster F, et al. Prophylaxis with rivaroxaban against venous thromboembolism (VTE): a cost-consequence analysis from the perspective of the Italian Healthcare Service. Value Health 2008;11:534.